ALPROLIX^®: the first EHL FIX
WITH >10 years OF REAL-WORLD EXPERIENCE^1–3

CONSISTENT BLEED REDUCTION AND
FEWER INJECTIONS VS SHL FIX IN THE UK⁹
Alleviating treatment burden for people living with haemophilia⁹

In a UK retrospective longitudinal analysis investigating clotting factor use and
bleeding outcomes associated with switching from SHL FIX, ALPROLIX (N=44):⁹

Improved bleed protection⁹

ABRs improved with ALPROLIX vs pre-switch SHL FIX⁹

Pre- and post-switch median ABR⁹

Reduced injection frequency⁹

One less injection per week after switching⁹

Before switch: 2.0 injections/week
After switch: 1.0 injection/week

p<0.001

Reduced factor consumption⁹

Reduced weekly factor consumption with ALPROLIX vs pre-switch SHL FIX⁹

Pre- and post-switch median factor consumption⁹

*Median change between pre- and post-switch ABR.^{9 †}Median within-patient reduction.⁹
ABR, annualised bleeding rate; FIX, factor IX; SHL, standard half-life.

The National Haemophilia Database (NHD) studied clotting factor use and bleeding outcomes associated with switching from SHL FIX to ALPROLIX prophylaxis:⁹

Within-patient comparison over a two-year period (sub-group analysis)⁹

Data analysed for 44/68 patients who were haemtrack compliant
with six months of pre- and post-switch data⁹

FIX, factor IX; NHD, National Haemophilia Database; SHL, standard half-life.

No safety data were collected.